LAUSR

Homeobox A5 (HOXA5) is a member of the HOX protein family which were implicated in serval critical process and was cancer-specific dysregulated in human cancers. However, its expression and function in human gastric cancer (GC) was still largely unknown. In this study, we confirmed for the first time that HOXA5 mRNA and protein was down-regulated in GC tissues and cell lines. Clinical data showed that low HOXA5 was significantly associated poor prognostic features, including large tumor size and advanced TNM stage. For 5-year survival, HOXA5 served as a potential prognostic marker of GC patients. Notably, HOXA5 inhibited cell viability, colony formation, proliferation, cell cycle progression and promoted apoptosis in vitro and in vivo. Furthermore, we demonstrated that HOXA5 expression was regulated by miR-196a. In GC tissues, miR-196a has an inverse correlation with HOXA5 expression. Conclusively, our results demonstrated that HOXA5 functions as a tumor suppressor in regulating tumor growth of GC under regulation of miR-196a, supporting its potential utility as a therapeutic target for GC.